BNP Paribas Financial Markets’s Humacyte HUMA Stock Holding History

BNP Paribas Financial Markets’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$164K	Buy	209,785 +170,650	+436%	+$158K	﹤0.01%	4322
2026 Q1	$23.7K	Sell	39,135 -1,061,702	-96%	-$1.1M	﹤0.01%	5034
2025 Q4	$1.06M	Buy	1,100,837 +1,009,097	+1,100%	+$1.43M	﹤0.01%	3067
2025 Q3	$160K	Buy	91,740 +42,701	+87%	+$83.7K	﹤0.01%	4108
2025 Q2	$102K	Buy	49,039 +35,325	+258%	+$67.9K	﹤0.01%	4010
2025 Q1	$23.4K	Sell	13,714 -899	-6%	-$3.38K	﹤0.01%	4495
2024 Q4	$73.8K	Buy	+14,613	New	+$72.3K	﹤0.01%	4282

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BNP Paribas Financial Markets's HUMA Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Humacyte (HUMA) stake by 436% in Q2 2026, buying an estimated $158K and bringing the position to 209,785 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

BNP Paribas Financial Markets first reported a position in HUMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.06M in Q4 2025. 147 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

BNP Paribas Financial Markets held 209,785 shares of Humacyte worth $164K as of Q2 2026.
BNP Paribas Financial Markets bought 170,650 Humacyte shares in Q2 2026, an estimated $158K.
Humacyte made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4322 holding.
BNP Paribas Financial Markets first reported a position in Humacyte in Q4 2024 and has held it in 7 quarters since.
BNP Paribas Financial Markets's Humacyte position peaked at $1.06M in Q4 2025.
147 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.